Overview

Salsalate in Patients Mild to Moderate Alzheimer's Disease

Status:
Active, not recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
The purpose of the study is to test the safety and tolerability of twice daily Salsalate in patients with mild to moderate Alzheimer's Disease. Half of the participants will receive Salsalate and half will receive placebo during the 1-year duration of the study.
Phase:
Phase 1
Details
Lead Sponsor:
Adam Boxer
Treatments:
Salicylsalicylic acid
Sodium Salicylate